233 related articles for article (PubMed ID: 37612600)
1. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
2. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
3. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
4. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
[TBL] [Abstract][Full Text] [Related]
6. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database.
Tian X; Yao Y; He G; Jia Y; Wang K; Chen L
Sci Rep; 2021 Jun; 11(1):12438. PubMed ID: 34127681
[TBL] [Abstract][Full Text] [Related]
8. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
9. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
10. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
13. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
14. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
15. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
17. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
18. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
19. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
[TBL] [Abstract][Full Text] [Related]
20. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]